Dalfaz SR, 10 mg 30 pcs

Pharmacodynamics

Alfuzosin is a quinazoline derivative active when administered orallyIt is a selective antagonist of postsynaptic alpha-1-adrenoreceptors with a peripheral site of action.In vitro pharmacological tests have demonstrated the selective action of alfuzosin on alpha-1-adrenoceptors located in the prostate, in the bladder triangle and in the prostatic part of the urethra.

Indications

Treatment of functional symptoms of benign prostatic hyperplasia.

As an adjunctive agent when using a catheter in acute urinary retention associated with benign prostatic hyperplasia.

Active ingredient

Composition

1 tablet contains:

first layer:

hypromellose 79.75 mg,

castor oil hydrogenated 13.5 mg,

ethylcellulose 20 5 mg,

Iron oxide yellow dye (E172) 0.25 mg,

silicon dioxide colloidal aqueous 0.5 mg,

magnesium stearate 1 mg,

second layer:

alfuzosin hydrochloride 10 mg,

mannitol 10 mg,

hypromellose 10 mg,

MCC 65 mg,

How to take, the dosage

Over the mouth, after meals, swallowed whole, 10 mg daily.

Auxiliary use when using a catheter for acute urinary retention associated with benign prostatic hyperplasia: Recommended dose is 1 tablet of 10 mg daily, after meals, starting from the first day of catheterization. The drug is used for 3-4 days, i.e. 2-3 days during application of the catheter and 1 day after its removal.

Interaction

When used with blockers of ? 1 -adrenoreceptor blockers (prazosin, urapidil, minoxidil) the hypotensive effect is increased, the risk of severe postural hypotension increases (the combination is not recommended).

The simultaneous use of Dalfaz SR with hypotensive drugs increases the risk of postural hypotension due to the additive effect (the combination should be used with caution).

Concomitant use with CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) increases alfuzosin plasma concentrations (use with caution).

Special Instructions

In some individuals, especially patients receiving hypotensive drugs, orthostatic hypotension with or without clinical symptoms (dizziness, sharp weakness, cold sweats) may develop within a few hours after taking alfuzosin (as after taking other alpha1-adreno-blockers). Orthostatic hypotension is usually transient and occurs usually at the beginning of taking the drug and usually does not require treatment withdrawal. If these phenomena occur, the patient should be in a horizontal position until they completely disappear. Patients should be advised of the possibility of these events before starting treatment.

Patients with orthostatic hypotension with clinical symptoms, patients with a history of significant hypotensive response in response to other alpha1-adreno-blockers should be cautioned when prescribing alfuzosin – more careful BP control is necessary, including when going horizontal.When going from horizontal to vertical position, especially at the beginning of treatment.

In patients with CHD, antianginal therapy should continue. If angina recurs or worsens, treatment with alfuzosin should be discontinued.

Impact on the ability to drive and operate machinery.Especially at the beginning of treatment, the possibility of dizziness and asthenia should be taken into account, which may affect the ability to drive and operate machinery.

Contraindications

Side effects

CNS and mental disorders: often – weakness, feeling of general discomfort, headache; infrequent – drowsiness, dizziness, cerebral ischemia (in patients with ischemic brain disease).

Systems: infrequent – tachycardia, palpitations, syncope, orthostatic hypotension; very rare – angina in patients with coronary heart disease, atrial fibrillation.

Gastrointestinal disorders: frequently – nausea, abdominal pain, dry mouth; infrequently – diarrhea; very rarely – damage to hepatocytes, liver disease with cholestasis.

Skin and allergic reactions: infrequent – rash, itching; very rare – urticaria, angioedema.

The whole body: often – asthenia; infrequent – skin hyperemia, edema, pain in the chest; very rare – priapism.

Overdose

Recommended combinations:

Similarities